| THE UROLOGY CENTER OF COLORADO | |||
| Site name: | The Urology Center of Colorado | Active Prostate Cancer Clinical Trials: | |
| Contact: | Clinical Development Support | That match your search: | No search performed |
| Phone: | Not Provided | ||
| Site email: | Not Provided | ||
The Urology Center of Colorado is the only fully inclusive urology center in the Rocky Mountain region. Led by 18 board certified or eligible physicians, TUCC strives to provide patients with exemplary urologic care at one location.
The TUCC model of comprehensive urologic treatment at one location was originally conceived in January 2004 as a way to eliminate delays in patient care. Located just north of Invesco Field in Denver, we provide treatment for all urologic conditions.
All outpatient urologic procedures are performed in the TUCC ambulatory surgery center. Major inpatient procedures continue to be performed at local hospitals. TUCC physicians currently staff the following hospitals: Craig Hospital, Lutheran Medical Center, North Suburban Medical Center, Porter Hospital, Presbyterian/St. Luke's Medical Center, St. Anthony Central Hospital, St. Anthony North Hospital and Swedish Medical Center.
 |
 |
 |
 |
 |
 |
Brett Abernathy, M.D., F.A.C.S. |
Richard Augspurger, M.D., F.A.C.S. |
Eric Gross, M.D. |
Richard Heppe, M.D. |
Elias Hsu, M.D. |
Mark Jones, M.D. |
 |
 |
 |
 |
 |
 |
Lawrence Karsh, M.D., F.A.C.S. |
Donald May, M.D. |
Jesse Mills, M.D. |
Juan Montoya, M.D., F.A.C.S. |
Ferdinand Mueller, Jr., M.D. |
Alexander Philpott, M.D. |
 |
 |
 |
 |
 |
 |
David Ragan, M.D. |
Stephen Ruyle, M.D., F.A.C.S. |
Craig Sakurada, M.D., F.A.C.S |
Brian Smith, M.D. |
Carsten Sorensen, M.D. |
Reginald Westmacott, M.D. |
| TRIAL ID | TITLE | TRIAL PHASE |
|---|---|---|
| NCT01242748 | An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy | Phase 3 |
| NCT00928434 | A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment | Phase 3 |
| NCT01252693 | Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer | Phase 2 |